Over the course of the first six months of 2022, Sanofi expects to submit the first regulatory application for marketing authorization for a possible treatment of respiratory syncytial virus (RSV) in infants.
In a press release, the company states that it has received results from a phase II/III trial of the drug nirsevimab, which supports the drug candidate.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.